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covered. This text consists of 36 chapters, grouped into six parts. Most of the chapters are written by experts in the field from academia and industry. The goal is to have this book serve as a reference for graduate students, post-docs, and teachers and as an explanatory analysis for executives and scientists in biotech and pharmaceutical companies. Our hope is that this volume will provide a prologue to the field for both newcomers and those already active in the field.
The term "stem cell" appeared in the scientific literature as early as 1868 in the work of the eminent German biologist Ernst Haeckel. Haeckel, a supporter of Darwinian evolution, developed a number of phylogenetic trees to represent the evolution of organisms from common ancestors and called these trees Stammbaume ("stem trees"). In this context, he used the term Stammzelle ("stem cell") to describe the ancestor unicellular organism from which he presumed all multicellular organisms evolved. He referred to fertilized egg as the source that gives rise to all cells of the organism. Later, in 1887, Theodor Boveri and Valentin Hacker identified the earliest germ cells in animal embryos. In 1892, Valentin Hacker described stem cells as the cells that later in development produce oocytes in the gonads. Thus, in these early studies, the term stem cell referred to what we call the "germline lineage," "primordial germ cells," and "germline stem cells." In 1896, Edmund Wilson, an embryologist, reviewed the finding of these German scientists in his book The Cell in Development and Inheritance, which was published in English and became an inspirational work for a generation of embryologists and geneticists, especially in United States. Given his wide readership, Wilson is generally credited as having coined the term "stem cell."
Nuclear programming is the process that instructs specialized adult cells to form early pluripotent stem cells. Pluripotent stem cells posses the capacity to become any type of mature cell in the body and therefore have great potential for experimental and therapeutic purposes. Using the concept of "cellular reprogramming," Briggs and King in 1952 produced normal tadpoles by transplanting nuclei from blastula cells to enucleated eggs in the frog Rana pipens. However, transplanting nuclei from differentiated cells was achieved by John Gurdon in 1962 in the African clawed toad, Xenopus laevis, which is now known as the classic nuclear transfer experiment. It took more than another decade (1975) for Gurdon to succeed in producing healthy and sexually mature fertile frogs with functional muscle, beating hearts, well-differentiated eyes, and all of the other organs. This experiment provided the first clear evidence that cell specialization does not involve irreversible inactivation in the genes required for development of an animal. This conceptual framework led to the start of the field of nuclear reprogramming, and Gurdon became known as the "father" of nuclear reprogramming (cloning). It took almost another 10 years to clone an adult sheep, Dolly (in 1996) , by Kevin Campbell and Ian Wilmut of the Roslin Institute in Edinburgh, Scotland. This experiment dramatically extended Gurdon's concept from frogs to mammals. The Dolly-related work of somatic cell nuclear transfer was further extended to produce monkeys, cows, dogs, mice, and other animals. These remarkable contributions stimulated other researchers to think about using nuclear transfer to generate pluripotent human embryonic stem cells for cell replacement therapy. There are two routes to producing a living animal: (1) injection of a somatic cell nucleus into an enucleated egg (nuclear reprogramming) and (2) use of an embryo to produce embryonic stem cells. In a quite astonishing discovery, Kazutoshi Takahashi and Shinya Yamanaka of Kyoto University in Japan in 2006 for the first time turned adult mouse skin fibroblast cells into pluripotent cells. This breakthrough of inducing fribroblasts was achieved by stable transfection of only four transcription factors (Oct4, Sox2, Klf4, and c-Myc), and these are now referred to as induced pluripotent stem (iPS) cells. The discovery of iPS cells turned the field of nuclear reprogramming upside down. This work was extended and further confirmed by several groups that generated iPS cells from individuals with various neurodegenerative diseases, raising the hope of cell replacement therapy and making personalized medicine a reality. A section of this book with six chapters details the concepts behind nuclear reprogramming and induced pluripotent stem cells.
In 1868, Ernst Neumann suggested that hematopoiesis occurs in bone marrow. He used the term "stem cell" to refer to the common precursor of the blood system in 1912. The debate about the existence of a common hematopoietic stem cell continued for several decades until definitive evidence was provided in 1961 by two Canadian scientists, James Till and Ernest McCulloch. Blood and the system that forms it, known as the hematopoietic system, consists of many cell types with specialized functions (some of these include red blood cells, platelets, granulocytes, macrophages, B and T lymphocytes, etc). Generally, the hematopoietic system is destroyed by radiation and chemotherapeutic agents that kill dividing cancer cells. In order to quantitatively assess the radiation sensitivity of normal bone marrow cells, a colony-forming unit assay was developed by Till and McCulloch, who coined the term "pluripotent hematopoietic stem cells" (HSCs). Today, we know that the best locations for HSCs are bone marrow, umbilical cord blood, and embryonic stem cells. In 1959, for the first time, Edward Donnall Thomas of the University of Washington used HSCs for treating leukemia and lymphomas through bone marrow transplantation. The efficient expansion of HSCs in culture remains one of the major research themes of stem cell biology. Combined applications of genomics, proteomics, and gene therapy approaches will further help to widen the horizon for clinical applications. According to Irving Weissman of Stanford University Medical School, the progeny produced from hematopoietic stem cells exhibits properties that include self-renewal, differentiation, migration, and apoptosis. A few chapters in the third part of this book highlight of the use of HSCs for bone marrow cell therapy, heart transplantation, and cell replacement therapy for neurologic disorders.
The term "tissue engineering" was first used by Eugene Bell of MIT in 1984, and later was also used extensively by Wolter and Meyer in 1984. Tissue engineering combines cells, engineering, and materials methods with suitable biochemical and physiochemical factors to improve or replace biologic functions. In other words, it deals with the repair or replacement of portions of or whole tissues such as bone, blood vessels, bladder, skin, and artificial organs. According to Robert Langer and Joseph Vacanti, it "applies the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function or a whole organ." Powerful developments in the multidisciplinary field of tissue engineering have yielded a novel set of tissue replacement parts and implementation strategies. Scientific advances in biomaterials, stem cells, growth and differentiation factors, and biomimetic environments have created unique opportunities to fabricate tissues in the laboratory from combinations of engineered extracellular matrices ("scaffolds"), cells, and biologically active molecules. A section of this book with five chapters highlights recent developments in biomaterials, three-dimensional culture systems, lab-on-a-chip concepts, and microtechnologies used in attempts to understand stem cell biology.
Regenerative medicine is a new branch of medicine that attempts to change the course of chronic disease, in many instances regenerating failing organ systems lost due to age, disease, damage, or congenital defects. The term "regenerative medicine" was first referred to in 1992 by Leland Kaiser and then popularly used by William Haselstine of Human Genome Sciences. The term regenerative medicine is often used synonymously with tissue engineering, although those involved in regenerative medicine place more emphasis on the use of stem cells to treat diseases using cell therapies or transplantation methods. This field holds the promise of regenerating damaged tissues and organs in the body by stimulating previously irreparable organs to heal themselves. Regenerative medicine also empowers scientists to grow tissues and organs in the laboratory and safely implant them when the body cannot heal itself. A section in this book is entirely devoted to describing the use of stem cells in muscle repair and treating cardiac and urologic diseases.
Gurdon has spent much of his career deciphering the molecules and mechanisms that an egg uses to "rejuvenate" nuclei. We know a lot about nuclear transfer, but the question remains of how to regulate and control the most efficient way to reprogram the nucleus. Although both Gurdon's (nuclear reprogramming) and Yamanaka's (iPS) technologies can generate living animals, we do not know the molecular mechanisms underlying these two strategies. The potential of iPS cell technology in biology and medicine is enormous; however, it is still in its infancy, and there are many challenges to overcome before various applications can be used successfully. We still need to understand the components of oocytes or eggs used to depress somatic gene expression and discover the direct cell-type switches by overexpressed transcription factors. It is also important to identify the basis for the stability of the differentiated state of cells, which will help us to understand how egg-reprogramming factors operate. Finally, mapping of the "embryome" is a necessity, and is looks as though it will become available soon, which will help us to understand the intricacies and epigenetic imprints of embryos.
Many people have contributed to making our involvement in this project possible. We thank our teachers for their excellent teaching, guidance, and mentorship, which helped us to bring this educational enterprise. We are extremely thankful to all of the contributors to this book, without whose commitment this book would not have been possible. Many people have had a hand in the preparation of this book. Each chapter has been passed back and forth between the authors for criticism and revision; hence each chapter represents a joint composition. We thank our readers, who have made our hours putting together this volume worth it. We are indebted to the staff of Springer Science + Business Media (Humana Press), and in particular Mindy Okura-Marszycki and Vindra Dass for their generosity in giving time and effort throughout the editing of this book. This book is dedicated to memory of my late friend, Prof. Xiangzhong (Jerry) Yang of the University of Connecticut, Storrs, who was the first to clone a cow (Amy, the calf) and a strong proponent of stem cell research here in US and China. This book is also dedicated to memory of my late friend, Prof. C.M. Habibullah of the Deccan College of Medical Sciences, India, who was a strong supporter of stem cell research in India. We especially thank Prof. John Gurdon, a researcher of great distinction, for his kindness and support in writing the Foreword to this book. Last, but not least, we thank Shyamala Appasani for her understanding and cooperation during the development of this book.
This book is the first joint project of father and son. A portion of the royalties will be contributed to the Dr. Appasani Foundation, a nonprofit organization devoted to bringing social change through the education of youth in developing nations.
Waltham, MA Krishnarao Appasani Boston, MA Raghu K. Appasani xi I am very grateful to Krishnarao and Raghu Appasani for preparing this volume on the massively expanding fields of stem cells and regenerative medicine and for inviting me to offer a few introductory comments. The prospect of being able to rejuvenate cell types of almost any kind from easily accessible cells of an adult makes it realistic to envisage cell replacement. Most important, this possibility would provide a patient with new cells of their own genetic type, thereby avoiding the necessity of immunosuppression, as would be required for any cells derived from any other individual, except an identical twin. The great interest in this field has been enormously stimulated by the recent discovery of induced pluripotency stem cells but has depended on several much earlier discoveries, most notably on that of embryonic stem cells.
There has been something of a tidal wave of interest in stem cells and regenerative medicine as researchers all over the world become active in it. Almost every day there are new papers published on various aspects of pluripotency, and it would be hard, even for those intimately involved in experimental work of this kind, to keep up to date with every advance. It is therefore very valuable to have a volume of 36 contributions summarizing the current status of progress in the various fields that contribute to regenerative medicine. Krishnarao and Raghu Appasani have assembled the contributing chapters into six main areas, ranging from stem cell biology through tissue engineering and therapeutic possibilities. The component chapters will be valuable not only to those who are experimentally active in an aspect of regenerative medicine, but also to those concerned with potential therapeutic applications. This volume also contains a valuable historical perspective by the Appasanis explaining key events in the development of this field over the last 150 years.
Although there is great enthusiasm for the eventual therapeutic value of work in this field for human health, scientists are very cautious about the time scale of human benefit. Bone marrow cells have been of great clinical value for a number of years. However, there is a long way to go before the brain and heart, to take two examples, can benefit from laboratory-created stem cells. It is indeed remarkable that beating heart cells or dopamine-secreting brain cells can now be derived from human skin and can be proliferated in the laboratory. However, substantial advances will be needed for it to be possible to integrate these laboratory-grown cells into Foreword organs or tissues of living individuals and to arrange for these new cells to continue their newly acquired activity once transplanted into a patient. It is unlikely that a complex organ, often consisting of many different cell types, will soon be able to be constructed in the laboratory. The number of cells required for human therapy is also of concern, since a human heart or brain consists of more than 1 million million (1012) cells. On the other hand, some cells make their contribution by secreting products or by providing critical neural connections, and even 10,000 cells of one kind could be valuable, as, for example, in the retina of the eye. I believe there is a cautious optimism in this field. It is generally true that once scientists find out how to achieve a desired result to a small extent, it is only a question of time before this advance is made to work enormously more efficiently.
My last comment concerns the reliability and safety of stem cells in regenerative medicine. There is understandable concern that any stem cells used for therapeutic purposes should be completely free of potential cancer cells or potentially harmful viruses. However, I submit that a situation might be reached where, even though one patient may suffer, more than 99.9% of other patients may derive enormous benefit. I hope that the fear of an occasional harmful replacement cell will not discourage continuing attempts to derive replacement cells that could be of enormous therapeutic value for a great number of other patients.
